Valpione, Sara
Galvani, Elena
Tweedy, Joshua
Mundra, Piyushkumar A. http://orcid.org/0000-0001-7769-2939
Banyard, Antonia
Middlehurst, Philippa
Barry, Jeff
Mills, Sarah
Salih, Zena
Weightman, John
Gupta, Avinash
Gremel, Gabriela
Baenke, Franziska
Dhomen, Nathalie
Lorigan, Paul C. http://orcid.org/0000-0002-8875-2164
Marais, Richard http://orcid.org/0000-0001-7484-4183
Article History
Received: 29 November 2019
Accepted: 17 December 2019
First Online: 10 February 2020
Competing interests
: R.M. is a consultant for Pfizer and has a drug discovery program with Basilea Pharmaceutica. P.L. serves as a paid advisor/speaker for Bristol-Myers Squibb, Merck Sharp and Dohme, Roche, Novartis, Amgen, Pierre Fabre, Nektar and MelaGenix. P.L. reports travel support from Bristol-Myers Squibb and Merck Sharp and Dohme, and receives research support from Bristol-Myers Squibb. A.G. received honoraria and consultancy fees from Bristol-Myers Squibb and Novartis. The other authors declare no competing interests.